The influence of remimazolam and propofol on heart rate variability in patients with sepsis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500115273

Enrollment

Unknown

Registered

2025-12-24

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Remimazolam group:None

Propofol group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Altered mental status (e.g., Glasgow Coma Scale =22 breaths/minute Diagnostic criteria for sepsis: Meet the Sepsis 3.0 diagnostic criteria, which refers to life-threatening organ dysfunction caused by a dysregulated response of the body to infection. Sepsis 3.0 = infection with SOFA score >=2.

Exclusion criteria

Exclusion criteria: 1. The patient and their family voluntarily sign the informed consent form; 2. Adult ICU patients who meet the Sepsis 3.0 diagnostic criteria; 3. Patients who need bronchoscopy, and before bronchoscopy are either awake or lightly sedated with a RASS score of -2 or higher, or require sedation or deepened sedation (RASS -4 or -5). In addition, the sedatives used for bronchoscopy are propofol or remimazolam.

Design outcomes

Primary

Measure	Time frame
HRV-related parameters (total heartbeats, total normal heartbeats, average R-R, maximum R-R, minimum R-R);	—

Countries

China

Contacts

Public ContactBo Yao

Qilu Hospital of Shandong University (Qingdao)

icuyaobo@126.com+86 186 6180 0691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026